Skip to main content
SpringerLink
Log in

Management of Menopausal Symptoms in Breast Cancer Survivors

  • Chapter
  • First Online:
Breast Cancer Survivorship

  • 979 Accesses

Abstract

Menopausal symptoms are a common consequence of systemic therapy for breast cancer and can significantly impact on quality of life as well as affect treatment compliance. The most effective treatments available using exogenous hormones are generally cautioned against in women with a history of breast cancer and management of such symptoms can therefore pose a challenge to the health care professional. This chapter focuses on the current options for the treatment of vasomotor and urogenital symptoms in women who have had treatment for breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cancer Research UK (CRUK, 2011). www.cancerresearchuk.org/cancerstats/types/breast/incidence. Accessed 1 Oct 2015.

  2. Anderson DJ, Yates P, McCarthy N, Porter-Steele J. Younger and older womens concerns about menopause after breast cancer. Eur J Cancer Care. 2011;2:285–94.

    Google Scholar 

  3. Blaes AH, Kreitzer MJ, Torkelson C, Haddad T. Nonpharmacologic complementary therapies in symptom management for breast cancer survivors. Semin Oncol. 2011;38:394–402.

    Article  PubMed  Google Scholar 

  4. Carpenter JS, Andrykowski MA, Cordova M, et al. Hot Flashes in postmenopausal women treated for breast carcinoma. Prevelence, severity, correlates, management, and relation to quality of Life. Cancer. 1998;82:1682–91.

    Article  CAS  PubMed  Google Scholar 

  5. Harris PF, Remington PL, Trentham-Dietz A, et al. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage. 2002;23:501–9.

    Article  PubMed  Google Scholar 

  6. Dennerstein L, Dudley EC, Hooper JL, et al. A prospective population based study of menopausal symptoms. Obstet Gynecol. 2000;96:351–8.

    CAS  PubMed  Google Scholar 

  7. Kronenberg F. Hot Flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990;592:52–86.

    Article  CAS  PubMed  Google Scholar 

  8. Mom CH, Buijs C, Willemse PHB, et al. Hot flushes in breast cancer patients. Critical Reviews Oncology/Haematology. 2006;57:63–77.

    Article  Google Scholar 

  9. Savard J, Simard S, Blanchet J, et al. Prevalence, clinical characteristics and risk factors for insomnia in the context of breast cancer. Sleep. 2001;24:583–90.

    CAS  PubMed  Google Scholar 

  10. Stearns V, Ullmer L, Lopez L, et al. Hot flushes. Lancet. 2002;360:1851–61.

    Article  CAS  PubMed  Google Scholar 

  11. Rosenberg J, Holst-Larsen S. Hypothesis: pathogenesis of postmenopausal hot flushes. Med Hypotheses. 1991;35:349–50.

    Article  CAS  PubMed  Google Scholar 

  12. Neves-e-Castro M, Birkhauser M, Samsioe G G, et al. EMAS position statement: the ten point guide to the integral management of menopausal health. Maturitas. 2015;81:88–92.

    Article  PubMed  Google Scholar 

  13. Anderson D, Seib C, McGuire A, Porter-Steele J. Decreasing menopausal symptoms in women undertaking a web-based multimodal lifestyle intervention: The Women’s Wellness Program. Maturitas. 2015;81:69–75.

    Article  PubMed  Google Scholar 

  14. Schover LR, Jenkins R, Sui D, et al. Randomised trial of peer counselling on reproductive health in African American breast cancer survivors. J Clin Oncol. 2006;24:1620–6.

    Article  PubMed  Google Scholar 

  15. Greenlee H, Balneaves LG, Carlson LE, et al. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr. 2014;50:346–58.

    Article  Google Scholar 

  16. Borrelli F, Ernst E. Alternative and complementary therapies for the menopause. Maturitas. 2010;66:333–43.

    Article  PubMed  Google Scholar 

  17. Ladycare USA. 2015. http://www.ladycareusa.com/faqs. Accessed 27 Oct 2015.

  18. Royal College of Obstetricians and Gynaecologists. Alternatives to hormone replacement therapy for the management of symptoms of the menopause. 2010. 2010 Scientific Impact Paper No 6 September RCOG.

    Google Scholar 

  19. Royal College of Nursing (RCN). Menopause: lifestyle and therapeutic approaches. RCN guide for nurses, midwives and health visitors. London: RCN; 2014.

    Google Scholar 

  20. Garcia MK, Graham-Getty L, Haddad R, et al. Systematic review of acupuncture to control hot flashes in cancer patients. Cancer. 2015;121:3948–58.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Smith RL, Flaws JA, Gallicchio L. Does quitting smoking decrease the risk of hot flashes? A longitudinal analysis. Maturitas. 2015;82:123–7.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.

    Article  CAS  PubMed  Google Scholar 

  23. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419–27.

    Article  CAS  PubMed  Google Scholar 

  24. Holmberg L, Iversen OE, Rudenstem CM. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100:475–82.

    Article  CAS  PubMed  Google Scholar 

  25. Von Schoultz E, Rutqvist LE, Stockholm Breast Cancer Study Group. Menopausal hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100:475–8.

    Article  Google Scholar 

  26. Kenemans P, Bundred NJ, Foldart J, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptom: a double-blind, randomized, non-inferiority trial. Lancet Oncol. 2009;10:135–46.

    Article  CAS  PubMed  Google Scholar 

  27. Bertelli G, Venturini N, Del Mastro L, et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol. 2002;13:883–8.

    Article  CAS  PubMed  Google Scholar 

  28. Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol. 2006;24:1409–14.

    Article  CAS  PubMed  Google Scholar 

  29. Mohammed H, Russell JA, Stark R, et al. Progesterone receptor modulates ERα action in breast cancer. Nature. 2015;523:313–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. J Am Med Asso. 2006;295:2057–71.

    Article  CAS  Google Scholar 

  31. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol. 2009;27:2831–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Berhan Y, Berhan A. Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor symptom? A meta-analysis and meta-regression of randomized double-blind controlled studies. Ethiop J Health Sci. 2014;24:209–18.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG Trial N05C9. J Clin Oncol. 2010;28:3278–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Stearns V, Beebe KL, Ivengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003;289:2827–34.

    Article  CAS  PubMed  Google Scholar 

  35. Johnson JA, Hamadeh IS, Langaee TY. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies. J Natl Cancer Inst. 2015;107:dju437.

    Article  PubMed  Google Scholar 

  36. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97:30–9.

    Article  CAS  PubMed  Google Scholar 

  37. Toulis KA, Tzellos T, Kouvelas D, Goulis DG. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clin Ther. 2009;31:221–35.

    Article  CAS  PubMed  Google Scholar 

  38. Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 2010;28:5147–52.

    Article  CAS  PubMed  Google Scholar 

  39. Loprinzi CL, Qin R, Balcueva EP, et al. Phase III randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol. 2010;28:641–7.

    Article  CAS  PubMed  Google Scholar 

  40. Walaga DR, Rubin LH, Banuvar S, et al. Effects of stellate ganglion block on vasomotor symptoms: findings from a randomised clinical trial in postmenopausal women. Menopause. 2014;21:807–14.

    Article  Google Scholar 

  41. Crandall C, Petersen MS, Ganz PA, Greendale GA. Association of breast cancer and its therapy with menopause-related symptoms. Menopause. 2004;11:519–30.

    Article  PubMed  Google Scholar 

  42. Cella D, Fallowfield L, Barker P, et al. Quality of life of postmenopausal women in ATAC (“Arimidex”, tamoxifen, alone or in combinations) trial after completion of 5 years adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100:273–84.

    Article  PubMed  Google Scholar 

  43. Pagani O, Regan MM, Francis PA, et al. International Breast Cancer Study Group. Exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:1358–9.

    Article  PubMed  Google Scholar 

  44. Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436–46.

    Article  PubMed  Google Scholar 

  45. Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two randomised phase 3 trials. Lancet Oncol. 2015;16:848–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014;17:3–9.

    Article  CAS  PubMed  Google Scholar 

  47. Weigerink MA, Poortman J, Agema AR, Thijssen JH. Estrogen receptors in human vaginal tissue. Maturitas. 1980;2:59–67.

    Article  Google Scholar 

  48. Iosif CS, Batra S, Ek A, Astedt B. Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol. 1981;141:817–20.

    Article  CAS  PubMed  Google Scholar 

  49. Roy S, Caillouette JC, Roy T, et al. Am J Obstet Gynecol. 2004;190:1272–7.

    Article  CAS  PubMed  Google Scholar 

  50. Leiblum S, Bachmann G, Kemmann E, et al. Vaginal atrophy in postmenopausal women. The importance of sexual activity and hormones. JAMA. 1983;249:2195–8.

    Article  CAS  PubMed  Google Scholar 

  51. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23:259–63.

    Article  CAS  PubMed  Google Scholar 

  52. Nachtigall LE. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril. 1994;61:178–80.

    Article  CAS  PubMed  Google Scholar 

  53. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 1997;15:969–73.

    CAS  PubMed  Google Scholar 

  54. Goetsch MF, Lim JY, AB C. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2015;33:3394–400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2003;(4):CD001500.

    Google Scholar 

  56. Nilsson K, Helmer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency- a pharmacokinetic and pharmacodynamics study. Maturitas. 1992;15:121–7.

    Article  CAS  PubMed  Google Scholar 

  57. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol. 2002;99:555–62.

    Google Scholar 

  58. Will S, Ravipati A, Venuturumilli P, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptpr modulator. J Oncol Pract. 2012;8:144–8.

    Article  Google Scholar 

  59. Simmons CE, Kuchuk I, Freedman OC, et al. Are Estring® and Vagifem® equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy? Clin Oncol (R Coll Radiol). 2012;24:e128–9.

    Article  CAS  Google Scholar 

  60. Donders G, Bellen G, Neven P, et al. Effects of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. Eur J Clin Microbiol Infect Dis. 2015;34:2023–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Cold S, Cold F, Jensen MB, et al. Vaginal estrogens and risk of recurrence or death in women treated for estrogen receptor positive breast cancer. 2015. European Cancer Congress Vienna 25–29 Sept 2015.

    Google Scholar 

  62. Makubate B, Donnan PT, Dewar JA, et al. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108:1515–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, The Christie NHS Foundation Trust, Withington, Manchester, UK

    Helen Mitchell BSc (Hons), MA, MSc, DMedEth

  2. The Christie NHS Foundation Trust, Wilmslow, Manchester, UK

    Anne C. Armstrong MB, ChB, PhD

Authors
  1. Helen Mitchell BSc (Hons), MA, MSc, DMedEth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne C. Armstrong MB, ChB, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne C. Armstrong MB, ChB, PhD .

Editor information

Editors and Affiliations

  1. The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

    Alistair Ring

  2. The Royal Marsden NHS Foundation Trust, London, United Kingdom

    Marina Parton

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Mitchell, H., Armstrong, A.C. (2016). Management of Menopausal Symptoms in Breast Cancer Survivors. In: Ring, A., Parton, M. (eds) Breast Cancer Survivorship. Springer, Cham. https://doi.org/10.1007/978-3-319-41858-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-41858-2_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-41856-8

  • Online ISBN: 978-3-319-41858-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation